Sava Infond d.o.o. Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Sava Infond d.o.o. bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 6,100 shares of the medical device company’s stock, valued at approximately $474,000.

Other hedge funds have also made changes to their positions in the company. Versant Capital Management Inc acquired a new stake in shares of DexCom during the fourth quarter worth about $25,000. Private Trust Co. NA lifted its stake in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after acquiring an additional 245 shares during the period. TD Private Client Wealth LLC lifted its position in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC boosted its stake in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after buying an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new stake in shares of DexCom during the 4th quarter worth $38,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock worth $8,044,178 in the last ninety days. 0.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Cfra Research raised DexCom to a “hold” rating in a research note on Friday, March 21st. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Finally, Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and increased their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $99.82.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $69.47 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a one year low of $62.34 and a one year high of $141.99. The business’s 50-day simple moving average is $82.65 and its 200 day simple moving average is $77.02. The company has a market cap of $27.15 billion, a P/E ratio of 48.58, a PEG ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, sell-side analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.